| 王 婧,韩林华,鞠秋燕,周婷婷,胡 涛.温肺通痹汤联合甲泼尼龙对间质性肺疾病患者肺功能、血清KL-6、HMGB-1、IL-18水平及生活质量的影响[J].,2024,(23):4587-4591 |
| 温肺通痹汤联合甲泼尼龙对间质性肺疾病患者肺功能、血清KL-6、HMGB-1、IL-18水平及生活质量的影响 |
| Effects of Wenfei Tongbi Decoction Combined with Methylprednisoloneon Lung Function, Serum KL-6, HMGB-1, IL-18 Levelsand Quality of Life in Patients with Interstitial Lung Disease |
| 投稿时间：2024-05-24 修订日期：2024-06-20 |
| DOI：10.13241/j.cnki.pmb.2024.23.053 |
| 中文关键词: 温肺通痹汤 甲泼尼龙 间质性肺疾病 肺功能 涎液化糖链抗原-6 高迁移率族蛋白-1 白细胞介素-18 生活质量 |
| 英文关键词: Wenfei tongbi decoction Methylprednisolone Interstitial lung disease Lung function Salivary liquefied sugar chain antigen-6 High mobility group protein-1 Interleukin-18 Quality of life |
| 基金项目:江苏省科学技术厅计划项目（BE2016710） |
|
| 摘要点击次数: 18 |
| 全文下载次数: 9 |
| 中文摘要: |
| 摘要 目的：探讨温肺通痹汤联合甲泼尼龙对间质性肺疾病（ILD）患者肺功能、血清涎液化糖链抗原-6（KL-6）、高迁移率族蛋白-1（HMGB-1）、白细胞介素-18（IL-18）水平及生活质量的影响。方法：按随机数表法将如皋市中医院2022年2月~2023年12月期间收治的91例ILD患者分为对照组（甲泼尼龙治疗，n=45例）和观察组（温肺通痹汤联合甲泼尼龙治疗，n=46例）。对比两组疗效、临床症状的改善时间、肺功能指标[第1秒用力呼气容积（FEV1）、一氧化碳弥散量占预计值百分比（DLco%）、用力肺活量（FVC）]、血清KL-6、HMGB-1、IL-18水平、圣乔治呼吸问卷（SGRQ）评分和安全性。结果：与对照组相比，观察组治疗后呼吸困难、咳嗽、干湿啰音等临床症状、体征的改善时间更短，总有效率更高（P＜0.05）。与对照组相比，观察组治疗后FVC、FEV1、DLco%更高，血清KL-6、HMGB-1、IL-18水平、SGRQ评分更低（P＜0.05）。对照组总不良反应发生率为6.66%，观察组为8.69%，组间无差异（P＞0.05）。结论：温肺通痹汤联合甲泼尼龙治疗ILD，可促进患者临床症状和肺功能的改善，调节血清KL-6、HMGB-1、IL-18水平，提高患者的生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of wenfei tongbi decoction combined with methylprednisolone on lung function, serum salivary liquefied sugar chain antigen-6 (KL-6), high mobility group protein-1 (HMGB-1), interleukin-18 (IL-18) levels and quality of life in patients with interstitial lung disease (ILD). Methods: According to the random number table method, 91 ILD patients admitted to Rugao Traditional Chinese Medicine Hospital from February 2022 to December 2023 were divided into control group (methylprednisolone treatment, n=45 cases) and observation group (wenfei tongbi decoction combined with methylprednisolone treatment, n=46 cases). The curative effect, the improvement time of clinical symptoms, lung function indexes [forced expiratory volume in the first second (FEV1), carbon monoxide diffusion volume as a percentage of predicted value (DLco%), forced vital capacity (FVC)], serum KL-6, HMGB-1, IL-18 levels, St. George's Respiratory Questionnaire (SGRQ) score and safety were compared between two groups. Results: Compared with control group, the improvement time of clinical symptoms and signs such as dyspnea, cough, dry and wet rales in observation group after treatment was shorter, and the total effective rate was higher (P<0.05). Compared with control group, FVC, FEV1 and DLco% were higher in observation group after treatment, and serum KL-6, HMGB-1, IL-18 levels and SGRQ scores were lower (P<0.05). The total incidence of adverse reactions in control group was 6.66%, and that in observation group was 8.69%, which was no difference between the two groups(P>0.05). Conclusion: Wenfei tongbi decoction combined with methylprednisolone in the treatment of ILD, which can promote the improvement of clinical symptoms and lung function, regulate the levels of serum KL-6, HMGB-1 and IL-18, and improve the quality of life of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
